Condition: Non-small Cell Lung Cancer · Sponsor: Boehringer Ingelheim
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active surveillance, based on local practice guidelines. The main purpose of the study is to determine whether zongertinib can prolong disease-free survival compared to standard treatment. Safety and patient-reported outcomes are also assessed.
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| ClinRé 001-022 (Premier Cancer Care and Infusion Center) | Fresno, California, United States | Recruiting |
| OPN Healthcare, Inc. | Glendale, California, United States | Recruiting |
| University of California Irvine | Irvine, California, United States | Not Yet Recruiting |
| Sutter Health | Roseville, California, United States | Not Yet Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Sarcoma Oncology Center | Santa Monica, California, United States | Recruiting |
| University of California Los Angeles | Santa Monica, California, United States | Recruiting |
| Northern California Kaiser Permanente | Vallejo, California, United States | Not Yet Recruiting |
| George Washington University Cancer Center | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Mid Florida Hematology and Oncology Center | Orange City, Florida, United States | Recruiting |
| Piedmont Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Northwest Georgia Oncology Centers | Marietta, Georgia, United States | Recruiting |
+ 187 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07195695